FDA
-
-
-
-
-
-
-
FDA issues second complete response letter to Unicycive over OLC drug application
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Lowered to $23 at Brookline Capital Markets
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Boston Scientific Corporation (NYSE: BSX): Corcept Therapeutics, Inc. (NASDAQ: CORT); Nektar Therapeutics (NASDAQ: NKTR): and Unicycive Therapeutics, Inc.
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Unicycive Therapeutics (UNCY)
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); Five Below, Inc. (NASDAQ: FIVE); Maison Solutions Inc. (NASDAQ: MSS); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Raised to $22 at H.C. Wainwright
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Humana Inc. (NYSE: HUM); Jasper Therapeutics, Inc. (NASDAQ: JSPR); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law
-
330,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

